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We would like to invite you to attend the 83rd AnnualMeeting of the American Thyroid Association, held
October 16–20, 2013, in beautiful and historic San Juan, Puerto
Rico. We hope you will share the enthusiasm of the Program
Committee regarding the exciting spectrum of topics and
speakers.
The program features 2 plenary talks; 14 symposia; 15 Meet
the Professor (MTP) workshops; lectures by the recipients of
the Van Meter, Ingbar, Starr, and Braverman awards; the
annual Clark Sawin Historical Vignette; and a Multi-
disciplinary Tumor Board session. In addition, nearly 300 ab-
stracts will be presented in oral or poster format by ATA
members. The program sessions, a few of which will be high-
lighted here, address the latest advances and controversies.
Prior to the official start of the meeting, the ATA/AACE
Advanced Endocrine Neck Ultrasound Course will occupy
most of the day on October 16. The opening session that
evening will review the most important developments over
the past year in basic, clinical, and surgical thyroidology. The
speakers for this Year in Review session will be recognized
experts in those fields, Drs. Anthony Hollenberg, Megan
Haymart, and David Steward.
Recent discoveries have resulted in the successful differen-
tiation of mouse embryonic stem cells into functioning thyroid
follicles that, when transplanted into an athyroid mouse, can
restore euthyroidism (1). This stunning accomplishment, with
important basic and clinical implications, will be presented in a
plenary lecture by Dr. Sabine Costagliola. Dr. Arul Chinnaiyan,
a leader in the discovery of cancer-driving gene mutations and
the therapeutic applications of cancer genome sequencing (2),
will present the second plenary lecture,Application of Integrative
Sequencing for Precision Oncology.
The association between thyroid status and various global
aspects of metabolism such as metabolic rate and lipid levels
has been appreciated for decades. Recent advances in basic
and translational research have provided surprising insights
into the underlying mechanisms (3) and have greatly broad-
ened our appreciation of the clinical importance of the thyroid
in the regulation of metabolism (4–6). A MTP workshop with
Drs. Kevin Phillips and Koshi Hashimoto will discuss Thyroid
Hormone Regulation of Cholesterol and Liver Metabolism; and a
basic symposium on Thyroid Hormone Control of Metabolism
featuring Drs. Paul Yen, Miguel Lopez, and Pieter de Lange
will present the latest data on the multiple ways thyroid
hormones regulate energy metabolism, including important
effects through liver autophagy and sirtuins, as well as
through the regulation of central (hypothalamic) pathways.
The essential role of thyroid hormone in neurological de-
velopment also has been appreciated for decades. The un-
derlying mechanisms have been challenging to uncover. Yet,
recent advances have not only provided important insights
but have expanded our appreciation of the important roles
that thyroid hormones play in diverse areas of neurobiology,
including neural stem-cell commitment (7), hypothalamic
regulation of cardiovascular function (8), and development
of the visual and auditory systems (9). Drs. Barbara Deme-
neix, Bjo¨rn Vennstrom, and Douglas Forrest will discuss
these topics in a basic symposium on Thyroid Hormone and
Neurobiology.
Cancer is one of the most heavily studied and rapidly ad-
vancing areas of thyroidology, in large part due to advances
in our understanding of the molecular mechanisms of this
disease and the development of targeted therapies. The 83rd
Annual Meeting will provide numerous sessions to update
attendees on the latest advances and to provide opportuni-
ties to discuss ongoing controversies. A symposium on the
Molecular Underpinnings of Thyroid Cancer Development and
Growth will integrate basic, clinical, and translational data to
achieve a more comprehensive view of the topic. In fact, this
type of integration is a theme that the Meeting embraces in
numerous sessions. Dr. Thomas Giordano will present the
highly anticipated data on papillary carcinomas from The
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Cancer Genome Atlas (TCGA). Dr. Jaroslaw Jendrzejewski
will discuss long noncoding RNAs, and Dr. Edna Kimura will
discuss microRNAs in thyroid cancer. The day-to-day man-
agement of the indeterminate thyroid nodule has become an
area of intense debate with regard to the relative risks and
benefits of alternative strategies, including surveillance, di-
agnostic surgery, or now the development of molecular test-
ing to either try to ‘‘rule in’’ or ‘‘rule out’’ the diagnosis of
thyroid cancer (10,11). A symposium on the Diagnostic Testing
of Thyroid Nodules will include an overview of indeterminate
cytology, a review of molecular markers of thyroid cancer,
and a comparison of commercially available tests in the
analysis of thyroid nodules, by Drs. Scott Boerner, Yuri
Nikiforov, and Stefan Grebe respectively. This will be com-
plemented by another symposium on Molecular Diagnostic
Testing of Thyroid Nodules: Decision Making for the Clinician,
where Dr. Ralph Tufano will review decision-making for the
surgeon, and Drs. Susan Mandel and Bryan McIver will de-
bate decision-making for the endocrinologist. Increasingly,
molecular markers are serving as targets for small molecule
therapies in and out of clinical trials for locally advanced and
metastatic thyroid cancer (12,13). There will be a symposium,
Update on Novel Therapies for Thyroid Cancer: When to Start and
What to Use, during which Drs. Marcia Brose and Matt Ringel
will provide overviews of drugs approved, in trial, and in the
pipeline for differentiated and medullary thyroid cancers re-
spectively. Dr. Ann Gramza will present a series of clinical
cases to allow the panelists to work through their strategies in
management. Finally, there will be a surgical symposium
centered on Ongoing Controversies in the Surgical Management
of Thyroid Cancer, where Dr. Sara Pai will discuss prophylac-
tic central neck dissection for papillary thyroid cancer,
Dr. Brendan Stack indications for lateral neck dissection, and
Dr. Libby Grubbs operative strategies for microcarcinomas.
The Arthur Bauman Clinical Symposium will include a mul-
tidisciplinary panel highlighting everyday ethical dilemmas
for different specialists involved in thyroidology, including
endocrinologists, surgeons, and oncologists.
The MTP workshops will provide forums to facilitate dis-
cussion and debate, in addition to the presentation of data. A
few of the 15 MTP workshops will be highlighted here. It is
now established that T4 and T3 enter cells via specific trans-
porters such as MCT8 and Oatp1c1, and that mutations in
thyroid hormone transporters can be disease-causing (14,15).
An MTP workshop led by Drs. W. Edward Visser and Heike
Heuer will provide an update on this important field. The
discovery that 3-iodothyronamine (T1AM), a previously un-
appreciated thyroid metabolite, can have dramatic biological
effects was unexpected (16,17). The physiological role of
T1AM is still being unraveled, and an MTP session led by
Drs. Thomas Scanlan and Riccardo Zucchi will provide the
latest information. Recent advances in DNA sequencing and
other molecular techniques have invigorated clinical research
and are providing renewed impetus for the establishment of
large biorepositories and electronic registries to integrate
samples with clinical information, outcomes, and molecular
characterizations. Drs. Robert Smallridge and Michael Roehrl
will discuss their experiences in the establishment and main-
tenance of these critical services. Other MTP workshops will
include faculty from different specialties and will highlight
controversies in the management of thyroid lymphoma,
poorly differentiated, and anaplastic thyroid cancers, thyroid
cancer in children, thyroid cancer in pregnancy, and thyroid
disease in the elderly, as well as congenital hypothyroid-
ism, Graves’ disease in adults and children, and Graves’
ophthalmopathy.
Several popular traditions will continue this year. The Fel-
lows Program will proceed in parallel with the scientific
meeting and is open to trainees from both endocrinology and
surgery. A practicum in clinical thyroidology, Weird Thyroid
Function Tests: Their Interpretation and Management, will be
directed by Drs. Jeffrey Garber and Marius Stan and include
audience participation. Finally, the meeting will close on
Sunday with a Thyroid Cancer Tumor Board that will include
panelists from endocrinology, surgery, pathology, nuclear
medicine, and oncology discussing challenging cases.
We look forward to five days of discussion and exchange of
ideas among clinicians, researchers, educators, and trainees
from around the world involved in the advancement of
thyroidology and the care of patients with benign and ma-
lignant thyroid disease. Hopefully, there will be sun. There
will definitely be debate, advancement of science, and most
importantly, collegiality and friendship.
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